EE635 Real-World Cost-Utility of Faricimab vs. Current and Future Anti-VEGF Therapies in Patients With Neovascular Age-Related Macular Degeneration in Italy
Abstract
Authors
Camilla Porta Gianni Ghetti ANTONIO FASCI Laura Bianchino